06:01 PM EDT, 10/01/2024 (MT Newswires) -- Dianthus Therapeutics ( DNTH ) filed a registration statement Tuesday with the US Securities and Exchange Commission for the potential sale of up to $500 million of its securities from time to time in one or more offerings.

The filing covers debt securities, units, warrants, common and preferred shares, the company said.

Dianthus also plans to sell up to $200 million of its shares through TD Securities, according to the filing.

Net proceeds from any such sale will be used for development activities, working capital and general corporate purposes, it added.